Laddar...
Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for head and neck and colorectal cancer treatment, but many patients treated with cetuximab don't respond o...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Neoplasia Press Inc.
2013
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3819635/ https://ncbi.nlm.nih.gov/pubmed/24204198 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|